News >

Improving CAR T-Cell Therapies With Greater Understanding of Cancer Immunology

Caroline Seymour
Published: Tuesday, Oct 08, 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center

Eduardo Sotomayor, MD

The two FDA approved CD19-directed CAR T-cell constructs—axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah)—have revolutionized the field of oncology, and provided a foundation to create additional constructs to overcome resistance mechanisms and minimize treatment-related toxicity, said Eduardo Sotomayor, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication